Margarida Magalhaes (De Magalhaes) Silverman MD
Hematology/Oncology
Director Stem Cell Transplant
Join to View Full Profile
200 Hawkins DrUniversity Of Iowa Hospitals & ClinicsIowa City, IA 52242
Phone+1 319-384-9156
Fax+1 319-353-8383
Dr. Silverman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1989
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1986 - 1988
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1984 - 1986
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1981 - 1984
Univ Porto- Fac MedClass of 1978
Certifications & Licensure
IA State Medical License 1997 - 2027
OH State Medical License 1988 - 2006
PA State Medical License 1991 - 2004
IL State Medical License 1982 - 1990
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsRandomized Phase III SIERRA Trial ofI-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R Litzow
Journal of Clinical Oncology. 2025-01-10 - 1 citationsA novel Iowa-Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction.Kalyan Nadiminti, Kimberly J. Langer, Ehsan Shabbir, Mehrdad Hefazi, Lindsay Dozeman
Blood Cancer Journal. 2021-11-20 - 3 citationsSerious Adverse Events in Related Donors: A Report from the Related Donor Safe StudyMatthew D. Seftel, Pintip Chitphakdithai, John P. Miller, Hati Kobusingye, Brent R. Logan
Transplantation and Cellular Therapy. 2021-04-01
Abstracts/Posters
- Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell LymphomaMargarida Magalhaes Silverman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy in Recently Diagnosed Elderly Multiple Myeloma (MM) Patients. Safety a...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Other Languages
- Portuguese, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
